Epidemiologia

Background and Aim: Opioid use disorder (OUD) during pregnancy has become a major public health issue, with its prevalence rising significantly in recent years. The incidence of neonatal abstinence syndrome (NAS) has also surged, from 1.5 cases per 1000 hospital births in 1999 to 6.0 cases per 1000 in 2013. This study aims to identify and analyze the concerns faced by pregnant people in accessing OUD treatment on time, specifically focusing on New York. Methods: The pooled sample of 225,275 individuals represents pregnant patients with OUD who received treatment at substance use disorder (SUD) facilities across New York State between 2016 and 2020, using data from the TEDS-D database. This dataset includes all pregnant individuals diagnosed with OUD, with consistent criteria for treatment eligibility applied. Results: The adjusted odds ratio (AOR) for medication-assisted treatment (MAT) for OUD was 1.41 (95% CI 1.15, 1.72; p = 0.0008) for full-time employees and 1.11 (95% CI 0.91, 1.34; p = 0.32) for part-time employees, compared to unemployed individuals. Regarding marital status, the AOR for treatment access was 1.51 (95% CI 1.34, 1.70; p < 0.0001) for currently married individuals and 1.85 (95% CI 1.67, 2.06; p < 0.0001) for those who are divorced or widowed, compared to individuals who have never married. Discussion: Our study highlights key sociodemographic barriers that affect early access to care for pregnant individuals in New York. OUD continues to be a critical public health issue, particularly among pregnant people, who are exposed to heightened health risks for both themselves and their babies, due to societal perceived stigma related to use during pregnancy.

Background: Feminizing adrenocortical tumors (FATs) are an exceedingly rare subset of adrenal neoplasms, typically affecting adult men and characterized by an excess of estrogen, suppressed gonadotropins, and gynecomastia. Most FATs are malignant, with a poor prognosis and a high risk of recurrence. Case Presentation: We report the case of a 24-year-old male with bilateral gynecomastia, abdominal mass symptoms, and one year of unexplained infertility. A hormonal evaluation revealed elevated estradiol (90.1 pg/mL) and suppressed ACTH (2.6 pg/mL), with inappropriately normal cortisol levels (12.1 µg/dL). Imaging identified a right adrenal mass. The patient underwent open adrenalectomy, and histopathology confirmed stage II adrenocortical carcinoma (T2NxM0) with autonomous estradiol secretion, negative margins, and a Ki-67 index of 10%. Postoperatively, gonadal function normalized, and infertility resolved at two months. The multidisciplinary tumor board considered but did not initiate adjuvant mitotane, given the completely resected low-stage disease. Conclusions: This case illustrates the rare presentation of feminizing adrenocortical carcinoma with reversible infertility and highlights the importance of early recognition and close surveillance. In addition, our literature review of 12 male cases reported between 2015 and 2025 emphasizes gynecomastia as the hallmark presentation and discusses emerging evidence supporting active surveillance as a potential alternative to adjuvant mitotane in selected low-risk patients.

Background and Objectives: Measles is a highly contagious but vaccine-preventable disease with significant morbidity in the European region, including Romania, especially in the post-COVID-19 era with low vaccination rates which no longer provide herd immunity. The current study aims to show how vaccination reduces the disease burden. Methods: A study using 29,148 cases with measles-compatible features in Romania from the 2020–2024 period was performed, analyzing symptoms, complications, and hospitalization rates comparatively between vaccinated and non-vaccinated groups. Results: Our findings show substantial hospitalization rates reduction among vaccinated cases with an over 12% decrease—depending on the number of MMR doses—as well as reduced severity of clinical features, but no significant effect on disease duration. Conclusions: MMR vaccination provides protection beyond primary disease prevention, as it reduces the disease burden among measles cases by reducing disease-related hospitalizations and improving clinical outcomes.